An investigation of p53 in skeletal muscle aging.
aging
muscle atrophy
p53
sarcopenia
skeletal muscle
Journal
Journal of applied physiology (Bethesda, Md. : 1985)
ISSN: 1522-1601
Titre abrégé: J Appl Physiol (1985)
Pays: United States
ID NLM: 8502536
Informations de publication
Date de publication:
01 10 2019
01 10 2019
Historique:
pubmed:
30
8
2019
medline:
20
8
2020
entrez:
30
8
2019
Statut:
ppublish
Résumé
Age-related skeletal muscle atrophy is a very common and serious condition that remains poorly understood at the molecular level. Several lines of evidence have suggested that the tumor suppressor p53 may play a central, causative role in skeletal muscle aging, whereas other, apparently contradictory lines of evidence have suggested that p53 may be critical for normal skeletal muscle function. To help address these issues, we performed an aging study in male muscle-specific p53-knockout mice (p53 mKO mice), which have a lifelong absence of p53 expression in skeletal muscle fibers. We found that the absence of p53 expression in skeletal muscle fibers had no apparent deleterious or beneficial effects on skeletal muscle mass or function under basal conditions up to 6 mo of age, when mice are fully grown and exhibit peak muscle mass and function. Furthermore, at 22 and 25 mo of age, when age-related muscle weakness and atrophy are clearly evident in mice, p53 mKO mice demonstrated no improvement or worsening of skeletal muscle mass or function relative to littermate control mice. At advanced ages, p53 mKO mice began to die prematurely and had an increased incidence of osteosarcoma, precluding analyses of muscle mass and function in very old p53 mKO mice. In light of these results, we conclude that p53 expression in skeletal muscle fibers has minimal if any direct, cell autonomous effect on basal or age-related changes in skeletal muscle mass and function up to at least 22 mo of age.
Identifiants
pubmed: 31465716
doi: 10.1152/japplphysiol.00363.2019
pmc: PMC6850986
doi:
Substances chimiques
Trp53 protein, mouse
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1075-1084Subventions
Organisme : BLRD VA
ID : I01 BX000976
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG060637
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR071762
Pays : United States
Organisme : NHLBI NIH HHS
ID : T35 HL007485
Pays : United States
Organisme : NIA NIH HHS
ID : R41 AG047684
Pays : United States
Références
Physiology (Bethesda). 2019 Jul 1;34(4):232-239
pubmed: 31165685
Mol Cell. 1998 Nov;2(5):559-69
pubmed: 9844629
Mol Endocrinol. 2010 Apr;24(4):790-9
pubmed: 20197309
J Biol Chem. 2016 Aug 19;291(34):17496-17509
pubmed: 27358404
Genes Dev. 2008 Jun 15;22(12):1662-76
pubmed: 18559481
Oncogene. 2013 Oct 24;32(43):5129-43
pubmed: 23416979
Aging Cell. 2014 Feb;13(1):92-101
pubmed: 23941502
Am J Physiol Endocrinol Metab. 2013 Oct 1;305(7):E907-15
pubmed: 23941879
BMC Genomics. 2007 Mar 23;8:80
pubmed: 17381838
Physiol Genomics. 2003 Jul 07;14(2):149-59
pubmed: 12783983
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11851-6
pubmed: 18697945
J Biol Chem. 2015 Oct 16;290(42):25497-511
pubmed: 26338703
Am J Physiol Endocrinol Metab. 2014 Aug 1;307(3):E245-61
pubmed: 24895282
Genes Dev. 2000 Apr 15;14(8):994-1004
pubmed: 10783170
Blood. 2018 Feb 1;131(5):488-495
pubmed: 29141944
Nature. 2002 Jan 3;415(6867):45-53
pubmed: 11780111
Sci Rep. 2018 Oct 2;8(1):14710
pubmed: 30279494
J Biol Chem. 2014 May 23;289(21):14913-24
pubmed: 24719321
Nat Rev Cancer. 2009 Nov;9(11):831-41
pubmed: 19776746
J Appl Physiol (1985). 2018 Jan 01;124(1):40-51
pubmed: 28982947
Exp Gerontol. 2004 Mar;39(3):369-77
pubmed: 15036396
J Biol Chem. 2012 Aug 10;287(33):27290-301
pubmed: 22692209
Cell Metab. 2011 Jun 8;13(6):627-38
pubmed: 21641545
PLoS One. 2012;7(6):e39332
pubmed: 22745735
Lab Invest. 2018 Jul;98(7):844-855
pubmed: 29849125